Christopher Richard Anzalone Sells 11,520 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 11,520 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the transaction, the chief executive officer now owns 3,764,252 shares in the company, valued at $71,709,000.60. The trade was a 0.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Christopher Richard Anzalone also recently made the following trade(s):

• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.59, for a total transaction of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $21.24, for a total transaction of $567,362.88.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $19.75 on Thursday. The business has a 50-day moving average of $21.04 and a 200-day moving average of $22.55. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of -3.93 and a beta of 0.97. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $17.05 and a 1 year high of $39.83.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ARWR shares. Piper Sandler reduced their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and an average target price of $43.33.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its stake in Arrowhead Pharmaceuticals by 3.7% during the second quarter. Commonwealth Equity Services LLC now owns 34,663 shares of the biotechnology company’s stock worth $901,000 after buying an additional 1,250 shares during the last quarter. Rhumbline Advisers raised its position in shares of Arrowhead Pharmaceuticals by 2.9% in the 2nd quarter. Rhumbline Advisers now owns 383,029 shares of the biotechnology company’s stock worth $9,955,000 after acquiring an additional 10,924 shares in the last quarter. TD Asset Management Inc lifted its stake in shares of Arrowhead Pharmaceuticals by 90.8% in the 2nd quarter. TD Asset Management Inc now owns 54,200 shares of the biotechnology company’s stock valued at $1,409,000 after purchasing an additional 25,800 shares during the period. Victory Capital Management Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 67.3% during the 2nd quarter. Victory Capital Management Inc. now owns 41,090 shares of the biotechnology company’s stock valued at $1,068,000 after purchasing an additional 16,534 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in Arrowhead Pharmaceuticals by 2.4% during the second quarter. Arizona State Retirement System now owns 34,685 shares of the biotechnology company’s stock worth $901,000 after purchasing an additional 821 shares during the period. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.